Resolution

of the Federal Joint Committee on a Finding in the Procedure of Routine Practice Data Collection and Evaluations according to Section 35a, paragraph 3b SGB V:
Loncastuximab tesirine (relapsed or refractory diffuse large B-cell lymphoma) – Submission of study protocol and statistical analysis plan

of 22 January 2026

At their session on 22 January 2026, the Federal Joint Committee (G-BA) decided the following in the procedure of routine practice data collection and evaluations according to Section 35a paragraph 3b SGB V for the active ingredient loncastuximab tesirine (relapsed or refractory diffuse large B-cell lymphoma):

I. The routine practice data collection will not be carried out as it was found that the pharmaceutical company has not fulfilled their obligation - required by resolution of 17 July 2025 - to prepare a statistical analysis plan and study protocol prior to the implementation of the routine practice data collection.

II. The resolution will enter into force on the day of its publication on the website of the G-BA on 22 January 2026.

The justification to this resolution will be published on the website of the G-BA at www.g-ba.de.

Berlin, 22 January 2026

Federal Joint Committee (G-BA)
in accordance with Section 91 SGB V
The Chair

Prof. Hecken